between medication-treated diabetes and reduced progression of knee OA [OR 0.66,]. Medication-treated diabetes has no effect on knee OA incidence but reduces knee OA progression. The role of diabetes and anti-diabetic drugs in knee OA progression needs further exploration.
Introduction
Osteoarthritis is the most common form of joint disease affecting the ageing population and is characterized by a high rate of comorbid conditions. It has been shown that in patients with knee OA, the number of comorbidities was associated with a limitation of activities [1] , and more pain [2] , thus further increasing the OA burden.
Among other comorbidities, diabetes has been proposed as a possible independent contributor to OA incidence and severity. Several putative pathogenetic factors such as the accumulation of advanced glycation end products (AGEs), low-grade systemic inflammation, oxidative stress, and impaired neuromuscular control may link diabetes with OA [3] . An epidemiological association between diabetes and OA has been confirmed in a recent meta-analysis of 49 studies [4] . However, there is little data of whether diabetes can influence OA incidence or accelerate OA progression. One study demonstrated a cross-sectional association between diabetes and severe knee pain and impaired knee function, and an increased prospective risk of arthroplasty in diabetic OA patients [5] . These findings cannot be considered conclusive, as there is uncertainty regarding the value of joint arthroplasty as an outcome that Abstract Diabetes has been proposed as a factor involved in the pathogenesis of osteoarthritis (OA). Currently, there is a lack of research evaluating the prospective impact of diabetes on OA structural outcomes. In this study, we assessed the effects of medication-treated diabetes on incidence and progression of knee OA. We analysed longitudinal data from the multi-center, longitudinal, prospective observational Osteoarthritis Initiative (OAI) study. The main outcomes were radiographic OA incidence (development of Kellgren-Lawrence grade 2 with joint space narrowing, JSN) and progression (increase in semiquantitative JSN or a new knee replacement). For the study of incidence, we selected participants with KL <2 or /KL = 2 without JSN at baseline (incidence sample). To evaluate progression, we selected participants with baseline JSN <3 (progression sample). We used generalized estimating equations (GEE) logistic regression with adjustment for potential confounders to evaluate the effects of medication-treated diabetes on knee OA incidence and progression. We studied 3725 knees (3498 non-diabetic and 228 diabetic) in the incidence sample and 3594 knees (3335 non-diabetic and 259 diabetic) in the progression sample. Medication-treated diabetes did not have an effect on knee OA incidence (odds ratio, OR 0.53, 95% confidence interval, CI 0.23-1.5). There was an independent association Rheumatology INTERNATIONAL Electronic supplementary material The online version of this article (doi:10.1007/s00296-017-3676-7) contains supplementary material, which is available to authorized users.
accurately reflects OA-related pain, limited function, and structural deterioration [6, 7] . Moreover, the use of joint replacement as an outcome can only be justified on a subset of patients with more advanced OA. In another study, diabetes was only a predictor of joint space reduction in men with established knee OA [8] . Thus, it is still necessary to determine the independent effects of diabetes on OA-specific structural outcomes. Oral anti-diabetic drugs and insulin may also theoretically have an impact on OA progression and incidence [9, 10] . As these drugs are taken by the vast majority of diabetes patients nowadays [11] , it seems neither clinically relevant nor feasible to separate the effects of diabetes per se on OA from those of anti-diabetic medications.
Therefore, we performed this study to test the hypothesis of whether there are prospective effects of medicationtreated diabetes on knee OA incidence and progression in participants included in the Osteoarthritis Initiative cohort.
Methods

Patients
For the current study, we used longitudinal data obtained from the Osteoarthritis Initiative (OAI), which is publically available at http://oai.epi-ucsf.org.
The Osteoarthritis Initiative cohort consists of a progression subcohort (patients with symptomatic tibiofemoral knee OA, n = 1390), an incidence subcohort (subjects with increased risk of OA, n = 3284) and a reference control subcohort (n = 122). In this analysis, we used the longitudinal data from both the progression and incidence subcohorts. The main inclusion criteria were the following: age between 45 and 79 years for both subcohorts, symptomatic tibiofemoral knee OA for the progression subcohort, and the presence of established or putative risk factors for incident knee OA for the incidence subcohort. The OAI subjects were recruited and enrolled between February 2004 and May 2006 at four recruitment centres in the USA. This study received ethical approval from each recruitment centre. All participants provided written informed consent. The prespecified sample size was 5000 women and men (4000 in the incidence subcohort, 800 in the progression subcohort). The sample size was expected to provide adequate numbers of knees with incident and worsening OA-related structural and clinical changes to achieve the primary aims of the OAI study.
The information about previously diagnosed diabetes was collected from the self-reported Charlson Comorbidity Index. A validity of treated diabetes self-report has been demonstrated in several studies [12, 13] . To further enhance the validity of the exposure in the current analysis, we defined diabetes status based both on selfreporting of treated diabetes and documented use of prescription oral anti-diabetic drugs and/or insulin 30 days prior to baseline. All currently used (past 30 days) prescription medications were captured using the medication inventory method wherein the participant brings in all the medications they are currently taking, and the brand name, generic name or active ingredients are recorded and matched to an entry in an online medication dictionary [14] . Participants with no information about diabetes, reported diabetes treated with diet/non-treated diabetes or who developed diabetes during the follow-up period were excluded from the analysis, as well as those participants who did not have at least two knee X-rays upon follow-up.
The initial Incidence and Progression OAI subcohort assignments were based primarily upon KL readings at the OAI clinical centers, but as assignment to Incidence and Progression Subcohorts may not precisely reflect a participant's knee OA status, further central assessments could provide different grading results. Therefore, to study the effects of diabetes on the incidence of knee OA we selected participants who had both knees with either centrally confirmed KL <2 or KL2 without JSN from both Cohorts (incidence sample). In the selected participants all evaluable knees were analyzed. We analyzed all knees having baseline JSN <3 from both subcohorts. For the assessment of diabetes influence on knee OA progression, we analyzed all knees having baseline JSN <3 from both subcohorts thus minimizing the risk of collider bias.
Clinical measures
Height was measured in millimetres using a calibrated wall-mounted stadiometer. The measurement was performed twice in light clothing, without shoes, and during inspiration. Body weight was measured in kilograms with a calibrated standard balance beam scale. The measurement was performed twice in light clothing without shoes, heavy jewellery or wallets. BMI was calculated based on weight (in kg) divided by height (in cm) squared. We used the selfreported Western Ontario McMaster Osteoarthritis Index (WOMAC) (5-point Likert scale) for addressing pain and function to evaluate the severity of OA symptoms [15] . The possible range for pain was 0-20, for physical function −0 to 68. Higher WOMAC scores represent more severe pain or reduction in function.
Smoking history and education status were assessed using self-administered questionnaire. Prior knee surgery, family history of knee replacement, and Physical Activity Scale for the Elderly (PASE) were evaluated using interview.
Radiographic assessment
Posteroanterior weight-bearing knee radiographs were performed annually using a Synaflexer frame (Synarc, San Francisco, California, USA) allowing fixed standardised and reproducible knee position. X-ray interpretation was made centrally at Boston University by three readers. In case of a disagreement about the presence of radiographic OA (Kellgren and Lawrence grade 2 or greater) or disease worsening (defined either as an increase in Kellgren and Lawrence grade or as an increase in joint space narrowing grade), the reading was adjudicated by a panel of three readers. A consensus reading was achieved when at least two of the three readers agreed.
Case definitions
The cases of incident radiographic OA were defined as the new onset of a combination of joint space narrowing and KL grade 2 as suggested by Felson et al. [16] . We defined the cases of knee OA progression as worsening in JSN score or a new knee replacement. The endpoints were assessed annually with a follow-up duration of 48 months.
Statistical analysis
Analyses were performed on the incidence and progression samples and further stratified by the gender. Continuous variables are presented as mean (standard deviation, SE), and categorical variables as number (percentage). Baseline differences were assessed using Student's t test for continuous and chi-squared test for categorical variables. Although most of the continuous variables were not normally distributed, we used mean (SE) and Student's t test as the preferred statistics even in the setting of non-normally distributed data [17] .
We used logistic regression models to evaluate the relationship between the outcomes and medicationtreated diabetes at study entry. Generalized estimating equations (GEE) were used to adjust for the correlation between knees. The models were adjusted for body mass index (BMI), age, race, gender, smoking history, education status, history of prior knee surgery, family history of knee replacement, Physical Activity Scale for the Elderly (PASE), and subcohort assignment. These potential confounders were selected based on the literature data and clinical plausibility. The adjustment for the subcohort assignment was carried out as the inclusion criteria for both subcohorts were different. We did not adjust for baseline outcome variables as this approach has been shown to introduce bias [18] . In the progression sample we performed an additional adjustment for baseline KL score. The use of GEE allows one not to use imputation methods for the analysis as the participants with missing data are not excluded from the analysis [19] .
Sensitivity analyses
The sensitivity analyses were performed with additional stratification by BMI subgroups (<25, 25-30, and > 30 kg/ m 2 ), race (white, non-white) and using all self-reported diabetes (both treated and non-treated) as predictor.
GEE analyses were performed with the GEE package for R [20] . All analyses were made using R software, version 3.3.0. Figure 1 shows a flow chart of study participants. We included 1863 participants, 1749 (93.88%) of whom were non-diabetic and 114 (6.12%) diabetic, in the incidence sample. There were 3725 analysed knees, 3498 (93.88%) non-diabetic and 228 (6.12%) diabetic. The progression sample consisted of 3443 participants, 3191 (92.68%) of whom were not diabetic, and 252 (7.32%) were diabetic. In the progression sample we analysed 3594 knees, 3335 (92.8%) of them were non-diabetic and 259 (7.2%) diabetic. The follow-up time was 4 years.
Results
The baseline characteristics of the studied groups are given on Table 1 . At baseline, participants with diabetes from the incidence sample were older (by a mean of 2.95 years), had a higher BMI (by a mean of 3.73 kg/m 2 ), were more likely to be non-white than white, had less frequent family history of knee replacement, were less educated, and had lower levels of physical activity. Diabetic participants had more knee pain and had impaired knee function as reflected by increased WOMAC pain and WOMAC function scores. Diabetic participants had higher rates of knee KL 1-2 rates grades on both knees.
There were similar baseline differences between diabetic and non-diabetic participants from the progression sample. Diabetics were older by a mean 2.54 and more obese with a mean BMI higher by 3.8 kg/m 2 . Unlike the incidence sample, no differences were found in gender and diabetics had higher rates of knees with JSN grades 2 and 3. Table 2 shows the frequencies of the prescribed anti-diabetic drugs in the incidence and progression samples. The most commonly prescribed drug was metformin (more than half of the diabetic participants) followed by sulfonylureas, thiazolidinediones, insulins, meglitinides, and miglitol.
The frequencies of outcomes are presented on Table 3 . The rates of incident OA approximated 5% while the progression rates were close to 20%. Knee joint replacement accounted for almost 15% of the progression cases. Table 4 shows the results of unadjusted and adjusted GEE analyses of the association between medicationtreated diabetes and knee OA incidence and progression.
Diabetes was not associated with knee OA incidence in both crude and final models. There was no significant association of diabetes and knee OA progression in nonadjusted models. However, after adjustment for multiple covariates diabetes became associated with decreased risk of knee OA progression. This association remained significant after additional adjustment for baseline KL scores. In gender subgroups, there were no significant associations between medication-treated diabetes and knee OA incidence and progression in both adjusted and non-adjusted models.
Sensitivity analyses
The numbers of participants in the sensitivity analyses are presented in Supplementary tables S1-S2. Only a small percentage (about 10%) of diabetes patients had normal weight. The amount of participants with all self-reported diabetes was approximately 20% higher than those participants with medication-treated diabetes. The results of the sensitivity analyses are shown in Supplementary tables S3-S4. In the sensitivity analyses, there was no effect of either medication-treated or all self-reported diabetes on the incidence of knee OA. Medication-treated diabetes was associated with a reduced risk of knee OA progression in the overweight participants in adjusted models and in obese participants in both crude and adjusted models. There was an association of all self-reported diabetes with knee OA progression in obese patients in both non-adjusted and final models.
Discussion
In this study, we found that in an OAI cohort, medicationtreated diabetes had no effect on knee OA incidence but was independently associated with decreased progression of knee OA. 
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The strengths of this analysis are that it is based on a large population with a well-defined cohort that incorporated participants with both early and advanced knee OA. The population-based design increases the generalizability of the study findings, and reduces the risk of selection bias. Another strength of this study is the use of standardised and reproducible procedures for the knee radiograph acquisition and extensive adjudication process to determine KL and JSN grades. In addition, the use of recently proposed definition of incident knee OA [16] probably reduced the risk of misclassification of incident knee OA cases.
Our study also has several limitations. The most important one is that we did not differentiate between the effects of diabetes and anti-diabetic medications. The information on diabetes came from participant self-reporting and the information about prescribed anti-diabetic medications. However, the accuracy of self-report of treated diabetes has been shown to be sufficient for use in epidemiological studies [12, 13] . We also did not differentiate between type 1 and type 2 diabetes and we could not assess the duration of diabetes and the level of diabetes control.
The results contradict findings by Schett who showed that type 2 diabetes predicted the development of severe OA defined as arthroplasty in an analysis of prospective follow-up of the population-based Bruneck cohort [5] . As the authors point out, one explanation of their findings may be the different decision-making for arthroplasty in diabetic versus nondiabetic subjects. Theoretically, the difference can also be explained by the characteristics of the studied cohorts. In the Bruneck cohort, 44.9% of participants at baseline had signs of polyneuropathy indicating complicated diabetes and their median glycated haemoglobin was 7.2% [5] , which can be seen as poor diabetes control in accordance with current standards [21] . The Bruneck study participants were recruited in 1990, a considerable time before the results of the pivotal UKPDS study were published, which led to changes in the diabetes treatment paradigm towards more stringent glycaemic control [22] . Although the current study had no information on glycated haemoglobin levels, it can be speculated that in the pre-UKPDS era the less-aggressively treated diabetes had a different impact on OA severity as opposed to the diabetes treated after the introduction of new treatment guidelines.
In contrast with findings of Eymard et al. who showed joint space reduction in diabetic men with established knee OA [8] , we observed an independent association between treated diabetes and decreased knee OA progression. In comparison with the data by Eymard et al., our study has a larger sample size and larger proportion of subjects with diabetes. The characteristics of diabetic patients in the study by Eymard et al. and in this analysis differ in several ways. First, we analysed a sample of participants with medication-treated diabetes as opposed to Eymard et al. who did not specify what proportion of their patients had medication-treated diabetes or were only treated with lifestyle modifications. Based on general population data [23] , it may be suggested that up to 14% of patients were not treated with drugs. Thus, the differences in the medication status of the diabetes patients could significantly influence the results. Apart from their glucose lowering action, oral anti-diabetic drugs and insulin have been shown to have pleiotropic properties including anti-inflammatory [24, 25] and cartilage-protective effects [9, 10] . For example, the most commonly used anti-diabetic drug metformin reduces inflammation, decreases the number of Th17 cells and increases the number of Treg cells in a mice model of collagen-induced arthritis [26] . Therefore, it could be hypothesized that medications used to treat diabetes attenuate the deleterious effects of diabetes on the knee OA incidence and may even lead to decreased progression of knee OA.
In addition, the participants from the study by Eymard et al. were Caucasian while in our study a significant proportion (36-37% in the diabetes groups) was African-American. Whether ethnic differences in diabetes genetics and pathophysiology can explain the contradictory results to be tested in future studies? The ethnic composition of our study may also limit the external validity of our findings.
Our findings are in line with recently published results of Singapore Chinese Health Study, a prospective cohort of 63,257 Chinese men and women, which showed an inverse association of diabetes and the risk of total knee replacement thus suggesting a protective effect of diabetes and/or anti-diabetic medications on the knee OA [27] . Our results also concur with the findings of studies from South Korea and Sweden, showing no association between metabolic syndrome and radiographic knee OA [28, 29] . The finding of decreased knee OA progression in patients with medication-treated diabetes only after adjustment for multiple covariates may indicate that in crude analysis this effect was masked by stronger associated risk factors such as obesity.
A lack of diabetes effect on knee OA incidence is supported with the results of the sensitivity analysis, with no significant relationship shown. The findings of protective effect of diabetes on knee OA progression only in the overweight and obese subgroups may be due to the smaller sample sizes of the group of diabetic patients with normal weight. Another explanation may be different treatment approaches used in overweight/obese vs. normal weight diabetic patients. A lack of diabetes effect on knee OA progression in gender and race subgroups may be explained by the reduction of the statistical power resulting from the stratification.
Our findings are far from being conclusive but they indicate that, in general, treated diabetes does not have an impact on OA incidence. It should be pointed out that the diabetic group in this study probably represents a population of patients with different type of diabetes, different levels of diabetes control, and different diabetes treatment regimens. Recently, diabetes appeared as a highly heterogeneous disease with diverse genetic background resulting in various phenotypes [30] . Therefore, there still may be an opportunity that in subgroups of patients with particular phenotype of diabetes, poor diabetes control or taking particular anti-diabetic drugs there is a meaningful link between diabetes and OA incidence.
At this time, the clinical significance of our findings is uncertain. Further investigation of cartilage protective and anti-inflammatory effects of anti-diabetic drugs may probably lead to the discovery of new approaches to OA treatment.
In conclusion, in OAI participants, medication-treated diabetes was not associated with the incidence of knee OA but independently reduced knee OA progression. The underlying mechanisms of these findings need to be further investigated.
